Response to a monovalent 2009 influenza A (H1N1) vaccine

New England Journal of Medicine

Volumn 361, Issue 25, 2009, Pages 2405-2413

  Greenberg, Michael E ^a   Lai, Michael H ^a   Hartel, Gunter F ^a   Wichems, Christine H ^a   Gittleson, Charmaine ^a   Bennet, Jillian ^a   Dawson, Gail ^a   Hu, Wilson ^a   Leggio, Connie ^a   Washington, Diane ^a   Basser, Russell L ^a  

^a CSL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INACTIVATED VIRUS VACCINE; INFLUENZA A H1N1 VACCINE; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; AUSTRALIA; BACKACHE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; GROUPS BY AGE; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; INJECTION SITE TENDERNESS; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; OBSERVATION; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SERODIAGNOSIS; SINGLE BLIND PROCEDURE; SORE THROAT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 72449172862     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0907413     Document Type: Article

References (25)

1. DG statement following the meeting of the Emergency Committee. Geneva: World Health Organization, 2009. (Accessed November 30, 2009, at http://www.who.int/csr/disease/swineflu/4th-meeting-ihr/en/index.html.)
2. Pandemic (H1N1) 2009 - update 63. Geneva: World Health Organization, 2009. (Accessed November 30, 2009, at http://www.who.int/csr/don/2009-08-28/en/ index.html.)
3. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009;58(RR-8):1-52. [Erratum, MMWR Recomm Rep 2009;58:896-7.]
4. President's Council of Advisors on Science and Technology. Report to the president on U.S. preparations for 2009- H1N1 influenza. Washington, DC: White House, August 7, 2009. (Accessed November 30, 2009, at http://www.whitehouse. gov/assets/documents/PCAST-H1N1-Report.pdf.)
5. Kuehn BM. H1N1 vaccine. JAMA 2009;302:375.
6. Mathematical modelling of the pandemic H1N1 2009. Wkly Epidemiol Rec 2009;84:341-348
7. Henderson DA, Courtney B, Inglesby TV, Toner E, Nuzzo JB. Public health and medical responses to the 1957-1958 influenza pandemic. Biosecur Bioterror 2009;7:265-273
8. World Health Organization. Availability of a candidate reassortant vaccine virus for the novel influenza A (H1N1) vaccine development. June 2009. (Accessed November 30, 2009, at http://www.who.int/csr/resources/publications/ swineflu/ivr153-20090608-en.pdf.)
9. Idem. Summary of available candidate vaccine viruses for development of pandemic (H1N1) 2009 virus vaccines. July 2009. (Accessed November 30, 2009, at http://www.who.int/csr/resources/publications/swineflu/summary-candidate- vaccine.pdf.)
10. Talbot HK, Keitel W, Cate TR, et al. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine 2008;26:4057-4061
11. Kendal AP, Pereira MS, Skehel JJ, eds. Concepts and procedures for laboratory-based influenza surveillance. Atlanta: Centers for Disease Control, 1982.
12. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937-943 (Pubitemid 29140593)
13. CDC protocol of realtime RTPCR for influenza A (H1N1). (CDC reference no. I-007-05.) Geneva: World Health Organization, 2009. (Accessed November 30, 2009, at http://www.who.int/csr/resources/publications/swineflu/ CDCRealtimeRTPCR-SwineH1Assay-2009-20090430.pdf.)
14. Committee for Proprietary Medicinal Products. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. London: European Medicines Agency, 1996. (Publication no. CPMP/ BWP/214/96.) (Accessed November 30, 2009, at http://www.emea.europa.eu/pdfs/ human/bwp/021496en.pdf.)
15. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. May 2007. (Accessed November 30, 2009, at http://www.fda.gov/downloads/ BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/ Guidances/Vaccines/ucm091985.pdf.)
16. Neergaard L. Factory logjam could delay some swine flu shots. New York: Associated Press, August 18, 2009. (Accessed November 30, 2009, at http://news.aol.com/article/factory-logjam-could-delay-some- swine/448143.)
17. Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics 2006;118(3):e579-e585. (Pubitemid 46091609)
18. Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-yearold children. J Infect Dis 2006;194:1032-1039 (Pubitemid 44547642)
19. Parkman PD, Hopps HE, Rastogi SC, Meyer HM Jr. Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 1977;136:Suppl:S722-S730. (Pubitemid 8286955)
20. Sencer DJ, Millar JD. Reflections on the 1976 swine flu vaccination program. Emerg Infect Dis 2006;12:29-33.
21. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343-1351
22. Australian Government Department of Health and Ageing. Australian influenza surveillance report no. 11-18 to 24 July 2009. (Accessed November 30, 2009, at http://www.health.gov.au/internet/main/ publishing.nsf/content/cda- ozflu-24-7-09.htm.)
23. Zimmer SM, Burke DS. Historical perspective - emergence of influenza A (H1N1) viruses. N Engl J Med 2009;361:279-285
24. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009;361:1945-1952
25. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009;325:197-201.